

Idiopathic Pulmonary Fibrosis Market Set for Exponential Surge, Predicted to Hit USD 6.16 billion by 2030

This report provides a detailed quantitative analysis of the current idiopathic pulmonary fibrosis market trends and forecast estimations from 2022 to 2032,

PORTLAND, OREGON, UNITED STATES, May 17, 2023 /EINPresswire.com/ --Allied Market Research published a report, titled, "Idiopathic Pulmonary Fibrosis Market DD DDDD DDDD 000000000, 000000 0000000000,



Idiopathic Pulmonary Fibrosis Market Growth 2023

□□□□." The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

The Global Idiopathic Pulmonary Fibrosis Market Size was Valued at USD 3.12 billion in 2020 and is poised to Reach USD 6.16 billion by 2030, witnessing a Growing CAGR of 7.0% from 2021 to 2030.

Covid-19 Scenario

- There has been decline in the number of idiopathic pulmonary fibrosis patient visits in hospitals & clinics for idiopathic pulmonary fibrosis therapy (IPF) to avoid cross-contamination. Moreover, there has been apostponement of elective surgeries to take care of Covid-infected patients.
- The idiopathic pulmonary fibrosis market was impacted negatively by the outbreak of the Covid-19 pandemic. The demand for drugs reduced from retail pharmacies and online providers

due to reduced therapy sessions and treatments.

- · AstraZeneca Plc,
- Biogen Inc.,
- · Boehringer Ingelheim,
- F. Hoffmann-La Roche,
- · FibroGen, Inc.,
- · Mission Therapeutics.,
- · GNI Group Ltd,
- · Galapagos NV,
- · Biogen,
- Bristol-Myers Squibb Company.,
- Shiongi Co Ltd.

Based on drug type, the pirfenidone segment accounted for the highest share in 2020, holding around three-fourths of the global idiopathic pulmonary fibrosis market, and is expected to continue its leadership status during the forecast period. Moreover, this segment is projected to manifest the highest CAGR of 7.2% from 2021 to 2030. This is due to rise in adoption of pirfenidone drugs such as Esbriet and Pirespa across the world. The research also analyzes the nintedanib segment.

Based on distribution channel, the retail pharmacies segment accounted for the highest share in 2020, contributing to nearly half of the global idiopathic pulmonary fibrosis market, and is estimated to continue its lead position during the forecast period. This is attributed to rapid increase in rate of idiopathic pulmonary fibrosis among the

geriatric population, technological advancements, and lifestyle changes worldwide. However, the online providers segment is expected to portray the largest CAGR of 8.5% from 2021 to 2030. This is due to offers and discounts offered by providers and the availability of different types of drugs under a single platform.

Based on region, North America contributed to the highest market share in 2020, holding more than two-fifths of the global idiopathic pulmonary fibrosis market, and is projected to continue its lead in terms of revenue by 2030. This is attributed to high expenditure on R&D activities, presence of major players & their product availability, and well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to manifest the fastest CAGR of 8.9% during the forecast period, owing to improvement in R&D facilities and rapidly developing economic conditions.

0000000 000 000000: https://www.alliedmarketresearch.com/purchase-enquiry/4407

Key Benefits For Stakeholders

- An in-depth idiopathic pulmonary fibrosis market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
- A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
- The projections in this report are made by analyzing the current trends and future idiopathic pulmonary fibrosis market potential from 2021 to 2030, in terms of value.
- An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
- Key market players within the idiopathic pulmonary fibrosis market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the idiopathic pulmonary fibrosis market.

Our Market Research Solution Provides You Answer to Below Mentioned Question:

- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- · How far will the market grow in forecast period in terms of revenue, sales and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?

By Region Outlook

- North America
 (U.S., Canada, Mexico)
- Europe

(Germany, France, UK, Italy, Spain, Rest of Europe)

Asia-Pacific

(Japan, China, India, Rest of Asia-Pacific)

LAMEA

(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa

USA/Canada (Toll-Free): +1-800-792-5285, +1-503-894-6022

help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa Allied Analytics LLP + +1-800-792-5285 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/633825999

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.